StudyFix logoCreated by the thestudyfix.com founder

Year 3 Induction — Disease Index & Clinical Criteria

Disease Index · 62 diseases across 10 categories · concept-only lectures excluded

Criteria & Scores · 33 scoring systems, bundles, classifications, and mnemonics across 8 categories

C/P — Clinical Presentation
Inves — Investigations
Mng — Management
Special — Pathognomonic / disease-unique

Dermatology — Inflammatory

6 entries
1

Atopic Dermatitis

C/P
  • Chronic relapsing pruritic dermatitis; family history of atopy (asthma, allergic rhinitis)
  • Infants/toddlers: face, elbows, knees (crawl-rub areas)
  • Acute: red, dry, itchy patches; blisters → ooze → crust if scratched
  • Chronic: lichenification (thick skin, prominent markings) ± post-inflammatory hyperpigmentation
  • 70% positive family history; incidence 1–20% of children
Inves
  • Clinical (deck defers detailed Inves/Mng to clinical sessions)
  • Microscopy if biopsied: spongiosis + intraepidermal vesicles (acute); marked epidermal hyperplasia + dermal fibrosis (chronic / lichen simplex chronicus)
Mng
  • — (deck defers to clinical sessions)
Special
  • Type I hypersensitivity reaction
  • Loss-of-function filaggrin mutation OR reduced claudin-1 expression → tight junction failure in cornified layer
  • Prognosis: 50% clear by 3y, 66% by 6y, 90% by 20y
2

Seborrhoeic Dermatitis

C/P
  • Greasy, white, flaky scaling over erythematous patches; usually not painful unless infected/irritated
  • Age peaks: babies <3 months (cradle cap), adults 30–60y
  • Scalp (= dandruff when mild); face (eyebrows, eyelids, forehead, nasolabial folds); chest; creases of neck/arms/legs/groin
Inves
  • Microscopy: subacute dermatitis with spongiosis in epidermis + hair follicle epithelium; scales in follicular ostia with neutrophils; dilated follicular ostia; epidermal hyperplasia
Mng
Special
  • Link to Malassezia / Pityrosporum orbiculare yeast overgrowth
  • Adult increase in: Parkinson's disease, facial paralysis, obesity, zinc deficiency, HIV
  • Infant variant = cradle cap
3

Allergic Contact Dermatitis (ACD)

C/P
  • Inflammatory eruption at site of allergen contact in pre-sensitised person
  • Examples: poison ivy; nickel (most common in children — snap/watch/belt/jewellery sites); periumbilical reaction from trouser belt
  • Acute spongiotic dermatitis pattern → subacute → chronic (resembles lichen simplex chronicus)
Inves
  • Microscopy: marked spongiosis with vesicles; lower epidermis affected early; lymphocytes + eosinophils in infiltrate; necrotic keratinocytes absent
Mng
Special
  • Type IV cell-mediated delayed hypersensitivity
  • First exposure = sensitisation (memory T cells); second exposure = inflammatory lesion
  • Eosinophils on histology are the key marker vs ICD
4

Irritant Contact Dermatitis (ICD)

C/P
  • Inflammatory skin response to non-immune direct toxic effect of chemical/physical irritant
  • Causes: chemical burns (alkalis/acids), acute irritants (cosmetics), chronic irritants (detergents)
  • Diaper rash = most common infant ICD (prolonged contact with urine/stool chemicals)
Inves
  • Microscopy: upper-epidermis affected; marked ballooning degeneration with variable keratinocyte necrosis; neutrophils in necrotic areas; spongiosis slight/absent
Mng
Special
  • Direct epidermal damage: lipid barrier removal, cell membrane damage, denatured keratin
  • Neutrophils + upper-epidermal necrosis distinguish from ACD (which has eosinophils + lower-epidermal spongiosis)
  • Ulceration/erosions may be present (absent in ACD)
5

Nummular (Discoid) Eczema

C/P
  • Scaly, crusted, pruritic, coin-shaped plaques
Inves
  • Microscopy: subacute spongiotic dermatitis
Mng
Special
  • Endogenous dermatitis subtype
6

Pemphigus Vulgaris

C/P
  • Skin barrier failure → fluid, protein and heat loss; portal of entry for infection (grouped with TEN + burns in this regard by the deck)
Inves
Mng
Special
  • Listed in the deck only as an example of skin malfunction / barrier loss; no dedicated mechanism/management cards

Skin & Soft Tissue Infections

14 entries
7

Impetigo

C/P
  • Large epidermal blisters fill with clear fluid/neutrophils → pustule → ruptures easily → yellow crust
  • Scab = coagulated plasma, cell debris, extravasated blood cells
Inves
  • Clinical
Mng
  • Antistaphylococcal cover (gram-positive coverage implied by causative organism)
Special
  • Superficial epidermal infection; gram-positive, most commonly Staphylococcus aureus
8

Staphylococcal Scalded Skin Syndrome (SSSS)

C/P
  • Widespread confluent blistering + separation of upper epidermal layers
  • Original infection may be occult, upper respiratory tract, or middle ear
Inves
Mng
Special
  • Driven by staphylococcal exfoliative toxin (cleaves desmoglein 1)
  • Relatively good prognosis in infants, considerable mortality in adults
9

Folliculitis

C/P
  • Pus accumulation around hair shaft
  • Hairy areas: buttocks, thighs, bearded face, scalp
Inves
  • Clinical
Mng
Special
  • Bacterial infection of hair follicles; most often Staphylococcus aureus
10

Furuncle (Boil)

C/P
  • Tender, indurated swelling around a hair follicle with surrounding oedema
  • Common on back, neck
  • Steps: staphylococcal pilosebaceous infection → suppuration → central necrosis → spontaneous rupture
Inves
  • Clinical
Mng
  • Removal of affected hair follicle aids drainage; incision usually not necessary
  • "Blind boil" (no suppuration): antistaphylococcal antibiotics
Special
  • Associated with debility and diabetes mellitus
  • Iodine application aggravates spontaneous rupture
11

Carbuncle

C/P
  • Confluent boils forming indurated masses with multiple skin openings (infective gangrene of subcutaneous tissue)
  • Back and nape of neck (regions with less tissue vitality)
  • Older diabetic patients classically
Inves
  • Clinical
Mng
  • Initial: antibiotics + local magnesium sulphate (reduces oedema, softens centre)
  • Non-responding: surgical — cruciate incision with corners of flaps excised for drainage
Special
  • Usually S. aureus (sometimes streptococci, gram-negative bacilli)
  • Strongly associated with poorly controlled diabetes (check BG)
12

Hidradenitis Suppurativa

C/P
  • Multiple swellings (axilla, groin, perianal) discharging pus, subsiding, recurring after months
  • More common in women in tropical countries (perianal form more common in men)
Inves
  • Clinical
Mng
  • Prevent: local hygiene; avoid deodorant, depilation, shaving
  • Antibiotics: erythromycin + metronidazole
  • Surgical: excision of affected skin + split thickness skin grafting if conservative fails
Special
  • Chronic infection of apocrine sweat glands due to duct blockage
13

Cellulitis (non-necrotising)

C/P
  • Diffusely spreading infection of dermis and soft tissues
  • Borders are ill-defined (unlike erysipelas)
Inves
  • Clinical
Mng
  • TOC: parenteral penicillin
  • Severe: protein synthesis inhibitor ± cell wall agent
  • Other options: antistaphylococcal penicillins, cefazolin, ceftaroline, ceftriaxone
  • Other causative agents to consider: Haemophilus influenzae, Pneumococcus
Special
  • Most frequent agent: Streptococcus pyogenes (lytic enzymes — streptokinase, DNAase, hyaluronidase — facilitate spread)
  • Macrolide resistance increasing
14

Erysipelas

C/P
  • Superficial cellulitis with prominent lymphatic involvement
  • Sharply demarcated raised border (vs ill-defined cellulitis edge)
  • Face, arms, legs
  • Local redness + swelling + regional lymphadenitis + systemic high fever, chills
Inves
  • Clinical
Mng
  • Penicillin
Special
  • Group A beta-haemolytic streptococci
  • "Cellulitis + dermal lymphatic inflammation"
15

Acne Vulgaris

C/P
  • Disorder of pilosebaceous units
  • More prominent in men (androgens stimulate sebum)
Inves
  • Clinical
Mng
Special
  • Multifactorial: sebum overproduction; pilosebaceous canal keratin obstruction; distension by sebum/keratin; anaerobic Propionibacterium acnes proliferation; secondary pyogenic infection
16

Sebaceous Cyst (Epidermal Inclusion Cyst)

C/P
  • Smooth, soft or firm cyst with central punctum attached to skin
  • Face, scalp, neck, scrotum (anywhere sebaceous glands exist)
  • Absent on palms and soles (no sebaceous glands)
Inves
  • Clinical
Mng
  • Excision of cyst with complete cyst wall removal (retained wall = recurrence)
Special
  • Pathognomonic = central punctum
  • Complications: infection, Cock's peculiar tumour, sebaceous horn
17

Necrotising Soft Tissue Infections (NSTI / Necrotising Fasciitis)

C/P
  • Earliest: severe pain out of proportion to examination findings (ischaemia)
  • Skin often spared early (rich vascular collaterals)
  • Late "hard signs": blistering, crepitus, bullae, haemorrhagic blebs, obvious necrosis
  • Systemic: SIRS, sepsis, profound multi-organ shock
Inves
  • Gold standard: clinical diagnosis confirmed by operative exploration
  • Operative findings: pasty grey necrotic tissue; thin purulent "dishwater" fluid; lack of resistance to digital pressure along fascia; lack of bleeding; thrombosed vessels; muscles do not contract to electrocautery
  • "Finger test": surgeon's fingers easily dissect SC layer off deep fascia
  • LRINEC score (WBC, Hb, Na, glucose, creatinine, CRP); ≥6 → high suspicion (PPV 92%, NPV 96%); does not distinguish septic shock/death so don't rely solely on it
  • Suggestive labs: WBC ≥15,400/µL, Na <135
  • Imaging: plain X-ray (SC gas — specific but only 17–30% sensitivity); CT (fascial thickening/oedema, gas — high specificity, low sensitivity); MRI (T2 hyperintense signal at deep fascia/muscle — slow, don't delay surgery)
Mng
  • Immediate aggressive surgical debridement (single most important determinant of survival; >24h delay = 9× mortality)
  • Excision of all necrotic skin/SC/fascia/muscle back to healthy bleeding tissue
  • Planned second-look operation in 12–24h after resuscitation; serial debridements until no infection
  • Saline-soaked gauze dressing post-debridement
  • Amputation (guillotine first) if limb non-viable, non-functional, or extensive proximal spread
  • Diverting colostomy for perineal infections (faecal contamination control)
  • Empiric antibiotics: gram-positive (incl MRSA) + gram-negative + anaerobic
  • Clindamycin attenuates exotoxins (S. aureus, hemolytic strep M proteins, clostridia)
  • Add doxycycline/tetracycline if Vibrio/Aeromonas suspected
  • Antibiotic duration: ≥48–72h after systemic signs resolve + source control complete
  • IVIG: theoretical benefit on streptococcal superantigens; INSTINCT study found no 6-month survival benefit
  • Hyperbaric O₂: theoretical benefit, failed to show mortality/LOS benefit; cost/availability limit use
Special
  • Hyaluronidase degrades fascial adhesions → rapid spread along fascial planes
  • Avascular fascia liquifies (diagnostic feature)
  • Anaerobic gas production (CO₂, H₂, N₂, H₂S, CH₄) → crepitus + radiographic gas
  • 4 types:
    • Type I (55–80%) — polymicrobial (Streptococcus + Bacteroides); risk factors: diabetes, obesity, immunosuppression, CKD, cirrhosis, malignancy, alcohol abuse
    • Type II (10–15%) — monomicrobial (β-haemolytic Streptococcus or Staphylococcus aureus); post-trauma/surgery/IV drug use; M proteins → polyclonal T cell activation
    • Type III — marine exposure (Clostridium species, Vibrio vulnificus from warm coastal seawater/raw oysters); 30–40% mortality; isolated Clostridium = up to 4× higher mortality; add tetracycline
    • Type IVAeromonas hydrophila, Candida (immunocompromised), Zygomycetes (immunocompetent); penetrating trauma or burns; add antifungal
  • Obesity paradox: protective on in-hospital mortality
  • Paediatrics: predisposed by varicella lesions, IM injections; usually monomicrobial S. pyogenes
  • DKA → higher mortality, longer hospital stays
18

Fournier's Gangrene

C/P
  • NSTI affecting genitourinary tract / perineum
Inves
  • As for NSTI
Mng
  • As for NSTI; orchiectomy rarely needed (testicular blood supply preserved)
  • Diverting colostomy often needed for soilage control
Special
  • Anatomical-site variant of NSTI
19

Ludwig Angina

C/P
  • NSTI involving submandibular and sublingual spaces
Inves
  • As for NSTI
Mng
  • As for NSTI
Special
  • Anatomical-site variant of NSTI
20

Diabetic Foot Infection

C/P
  • Diabetic patient with chronic plantar ulcer, new deep tracking, malodorous oedematous erythematous foot, extreme pain on palpation
  • Doppler may show biphasic pulses
Inves
  • Local susceptibility patterns + previous antibiotic exposure + prior pathogens guide empirical therapy
Mng
  • Empiric options: cefazolin, ceftriaxone, cefoxitin, ceftaroline, ampicillin-sulbactam, piperacillin-tazobactam, a carbapenem; daptomycin/linezolid with gram-negative cover
  • MRSA cover: vancomycin, telavancin, ceftaroline, daptomycin, tigecycline, linezolid
Special
  • Most common pathogen profile: gram-positive cocci
  • Other: gram-negative bacilli and anaerobes
  • Chronic wounds may have resistant pathogens
  • High risk for progression to NSTI of the foot (neuropathy + PVD + chronic ulcer)

Sepsis & Shock Syndromes

8 entries
21

Haemorrhagic / Hypovolaemic Shock

C/P
  • Brain hypoperfusion: anxiety (initial) → diminished consciousness (later)
  • Renal: reduced urine output
  • Skin: pale, cold, clammy (sympathetic overactivity)
  • Capillary refill >2s (prolonged)
  • Pulse: thready
  • Associated: thirst, air hunger
  • Tachycardia, tachypnea, hypotension in setting of acute blood loss
  • ATLS 4-stage classification (% blood loss / cap refill / peripheries / HR / BP / RR / urine output / consciousness):
    • Stage 1: <15% / <2s / warm / <100 / normal / 14–20 / >30 / slightly anxious
    • Stage 2: 15–30% / >2s / cool / >100 / normal or narrow pulse pressure / 20–30 / 20–30 / agitated
    • Stage 3: 30–40% / 5s / colder / >120 / low / 30–40 / 5–15 / confused/lethargic
    • Stage 4: >40% / >5s / coldest / >140 / very low / >35 / negligible / unresponsive
  • Compensation sequence: peripheral vasoconstriction → tachycardia → postural hypotension → recumbent hypotension
Inves
  • ABGs + lactate (gauge severity, response): metabolic acidosis, base deficit, high lactate (anaerobic metabolism)
  • Tachypnoea drives compensatory respiratory alkalosis
  • Hb/Hct not useful acutely (transcapillary refill + IV fluids must occur first before drop is appreciable)
Mng
  • Two principles: stop the bleed + replace the loss
  • Wound compression
  • Two wide-bore peripheral IV lines
  • IV fluids until blood components available
  • Low-volume resuscitation + early blood component therapy (minimise coagulopathy of trauma)
  • Permissive hypotension (raising BP may induce rebleeding)
  • Don't over-fluid (dilutes coagulation factors)
  • Blood component ratio PRBC:FFP:Platelets = 1:1:1
  • Exclude associated head injury before suturing scalp wounds
  • Antibiotics, tetanus prophylaxis, analgesia as indicated
  • Reassess vitals + repeat ABGs
Special
  • BP is the LAST parameter to drop — normal BP does NOT rule out significant blood loss
  • Major Haemorrhage Protocol triggers: replacement of entire blood volume in 24h; >8–10 RBC units in 24h; >50% blood volume in 3h; loss ≥150 ml/min; ≥4 RBC units in 1h with ongoing bleeding; predicted need ≥8 RBC units in 2h
  • TXA: give ASAP, 1g bolus over 10 min then 1g infusion over 8h; every 15-min delay decreases survival by 10%
  • Lethal triad — hypothermia + acidosis + coagulopathy
22

Sepsis / Septic Shock

C/P
  • Classical Sepsis 1: infection + SIRS → severe sepsis (organ dysfunction) → septic shock (CV collapse needing vasopressors)
  • SIRS criteria (≥2): T ≥38 or ≤36; HR ≥90; RR ≥20 or PaCO₂ ≤32; WBC ≥12,000 or ≤4,000 or ≥10% bands
  • Sepsis 3 (2016) definition: life-threatening organ dysfunction caused by dysregulated host response to infection
  • qSOFA (≥2 of 3): RR >22; altered mental status; SBP <100 — bedside screen
  • Septic shock (Sepsis 3): vasopressors needed for MAP >65 + lactate >2.0 despite adequate fluid resuscitation
  • Classic appearance: unwell, hypotensive, flushed cheeks, warm peripheries, bounding pulses (early "warm" shock; SVR ↓, CO ↑)
  • Late distributive shock: cool skin, hypotension (despite distributive aetiology)
Inves
  • Blood cultures BEFORE antibiotics (do not delay therapy)
  • Lactate (resuscitation marker, target normalisation)
  • SOFA score: PO₂/FiO₂, platelets, bilirubin, MAP/vasopressors, GCS, creatinine/urine output; SOFA ≥2 = ≥10% mortality
  • Imaging to identify source
  • Rapid antigen assay if fungal suspected
Mng
  • Sepsis Six bundle (within first hour): supplemental O₂; IV access + crystalloid; urinary catheter; blood cultures before antibiotics; empirical antibiotics; lactate level
  • O₂: high flow 15 L/min via non-rebreathe, target sats >94%
  • Fluids: crystalloid 30 ml/kg (or 20 ml/kg boluses 0.9% saline or Hartmann's, max 60 ml/kg if hypotensive)
  • Ensure Hb >7 g/dl
  • Source control as soon as possible (e.g., ERCP for cholangitis)
  • Surviving Sepsis Campaign quantitative targets: CVP ≥8 mmHg; MAP ≥65 mmHg; urine output ≥0.5 ml/kg/h; ScvO₂ ≥70%; normalise lactate
  • Vasopressors if hypotensive despite fluids
  • First-line vasopressor: centrally-administered noradrenaline
  • Dobutamine if myocardial dysfunction
  • Dopamine NOT for "renal protection"
  • Phenylephrine NOT recommended
  • IV hydrocortisone if hypotension responds poorly to fluids+vasopressors (max ≤300 mg/d)
  • Tidal volume target 6 ml/kg; plateau pressure ≤30 cmH₂O; PEEP to avoid lung collapse
  • Glucose upper target 180 mg/dl
  • Stress ulcer ppx: PPI or H2 blocker
  • DVT ppx: LMWH or unfractionated heparin
  • 7.6% mortality increase per hour delay in antibiotics
Special
  • Sepsis 3 abandoned SIRS criteria and "severe sepsis" term
  • qSOFA has poor sensitivity for early sepsis screening
  • Lactic acidosis causes: microcirculatory lesions; hypotension; mitochondrial injury; decreased hepatic clearance
  • US: ~750,000 cases/year, ~30% mortality
23

Anaphylactic Shock

C/P
  • Rapid onset of shock after known allergen exposure
  • Airway: dyspnea, wheezing, swollen face/lips, stridor
  • BP low, HR high
  • No fever
  • Wheezes on auscultation = airway involvement / bronchospasm
Inves
  • Primarily clinical
  • Monitor sats, vitals, GCS/AVPU, rashes/oedema
Mng
  • ABCDE approach
  • Oxygen + consider early intubation (laryngeal oedema can progress rapidly)
  • IV crystalloids
  • IM adrenaline (life-saving)
  • IV corticosteroids
  • Antihistamines
Special
  • Distributive shock category
  • Always consider early intubation before airway compromise becomes impossible
24

Cardiogenic Shock

C/P
  • In the deck primarily as differential in:
    • Elderly trauma patient with chest pain post-MVC (tension pneumothorax, tamponade, or MI causing the crash)
    • Post-op patient with oliguria + hypotension (rule out MI)
  • Flat neck veins ↔ excludes cardiogenic shock (helps differentiate)
Inves
  • 12-lead ECG, cardiac enzymes, troponin
  • Bedside ultrasonography (caval filling for volume status)
  • CVP, urinary output
Mng
  • Exclude hypoxia and hypovolaemia
  • High flow O₂
  • ABG, Hb, troponin
  • Seek senior advice
Special
  • Elderly with beta-blocker therapy → lack of tachycardia may falsely reassure
  • Normal BP in chronically hypertensive elderly may represent severe relative hypotension
25

SIRS / MODS

C/P
  • SIRS = systemic manifestations of inflammation: fever (or hypothermia), elevated WBC, tachycardia, tachypnea
  • MODS: sequential failure of distant organs — pulmonary (ARDS), hepatic, intestinal, renal, cardiac
Inves
  • As per sepsis workup
Mng
  • Early enteral feeding + adequate resuscitation to maintain gut mucosal barrier and prevent translocation
  • Treat underlying source
Special
  • "Gut is the motor of critical illness"
  • Gut failure pathway: gut-associated lymphoid tissue failure + villous atrophy → colonisation by aerobic gram-negative bacilli → endotoxin translocation across gut wall → mesenteric lymph node macrophage activation → massive IL-6 + TNF release → SIRS + MODS
  • Sepsis 3 (2016) abandoned the "severe sepsis" term
26

Toxic Shock Syndrome (Wound TSS)

C/P
  • Acute onset multi-organ illness resembling severe scarlet fever
  • ~50% post-surgical cases present within 48h of operation
  • Initial: diarrhoea, vomiting
  • Initial signs: high fever, diffuse skin redness, hypotension
  • Late (1–2 days): diffuse desquamation
  • Surgical wound itself often looks unremarkable
  • Multi-organ pattern: shock, renal failure, coagulopathy, liver disease, respiratory distress, generalised erythematous rash, soft tissue necrosis at infection site
Inves
  • Clinical; wound culture
Mng
  • Wound drainage
  • Antibiotics — clindamycin (inhibits exotoxin production)
Special
  • Most common organism: S. aureus expressing TSS toxin-1, enterotoxin B, enterotoxin C
  • Rare: S. pyogenes (group A streptococci)
  • Originally classic in menstruating women (tampons); increasingly seen in post-surgical wounds
  • Superantigen mechanism: binds conserved MHC + TCR β chain → stimulates up to 20% of T lymphocytes → massive cytokine release (TNF, IL-1)
27

Tetanus

C/P
  • Lockjaw / trismus (jaw)
  • Neck spasm/rigidity
  • Risus sardonicus (sardonic smile — facial spasm)
  • Back spasms so intense they can cause spontaneous vertebral fractures
  • Laryngospasm and/or respiratory muscle spasm → respiratory failure
  • Incubation 7–8 days (range 3–21)
Inves
  • Clinical diagnosis only
  • No characteristic labs; wound/blood culture unhelpful
Mng
  • Human tetanus immunoglobulin
  • Airway protection (early tracheostomy)
  • IV magnesium (spasm prevention)
  • High-calorie replenishment
  • Benzodiazepines
  • Active immunisation as condition stabilises (natural disease confers NO immunity)
Prophylaxis (tetanus-prone wound criteria — any of)
  • Sustained >6h before surgery; significant devitalised tissue; puncture injury; soil/manure contact; associated clinical sepsis, foreign body, or compound fracture
  • Up to date + standard wound: no further vaccine
  • Up to date + high risk (e.g., manure): + immunoglobulin
  • Not up to date + tetanus-prone: reinforcing Td/IPV + immunoglobulin
  • Not up to date + non-prone: reinforcing Td/IPV only
  • Immunoglobulin standard 250 IU IM; high risk / >24h elapsed / heavy contamination / burns: 500 IU
Special
  • Clostridium tetani — gram-positive anaerobic spore-forming rod
  • Two exotoxins: tetanolysin, tetanospasmin
  • Tetanospasmin: neurotoxin blocking inhibitory neurotransmitter release → unopposed muscle contraction; acts at peripheral motor end plates, spinal cord, sympathetic nervous system
  • Infectious but NOT contagious (no person-to-person spread)
28

Malignant Hyperthermia

C/P
  • Rare, life-threatening response to inhaled anaesthetics or some muscle relaxants
  • Core temperature >40°C
  • Trismus, hypercapnia, tachycardia, tachypnea, hypertension, cardiac dysrhythmias, metabolic acidosis, hypoxaemia, myoglobinuria/coagulopathy
Inves
  • Clinical
Mng
  • Halt anaesthetic
  • Dantrolene over 48 hours
  • Sodium bicarbonate
  • Active cooling
Special
  • Autosomal dominant with variable penetrance
  • Mechanism: abnormal calcium metabolism in skeletal muscle → heat generation

Hospital-Acquired Infections

5 entries
29

Surgical Site Infection (SSI)

C/P
  • Erythematous, oedematous, tender wound; bacterial count >100,000 organisms/g tissue
  • Most common early post-op fever cause traditionally blamed on atelectasis; SSIs typically present later
  • 20% of surgical patients acquire nosocomial infections; SSI = 3rd most common form
  • 1–12% complication rate across all operations
  • Operation-specific rates: inguinal herniorrhaphy 2%; cholecystectomy 3%; appendectomy 5%; thoracotomy 6%; colectomy 12%
Inves
  • Septic screen: blood cultures, FBC + CRP, MSU, aspiration of pus (preferred to swab), CXR
Mng
  • Source control (incision/drainage)
  • Antibiotics
  • Remove/change lines
  • Infection control measures
Special
  • Endogenous source (primary): patient's own flora; e.g., perforated appendix
  • Exogenous source (secondary/HAI): operating theatre or ward
  • Most common bacterial source in groin hernia repair = patient's skin
  • Highest predisposed procedures = GI (especially colon opened)
  • Risk of death 4× higher; cost $12,000–30,000 per infection; LOS +3–7 days
  • Bacterial translocation can occur in as little as 30 minutes when gut barrier breached
30

Ventilator-Associated Pneumonia (VAP) / HAP / HCAP

C/P
  • VAP: pneumonia occurring 48–72h after endotracheal intubation
  • Most common ICU infection for surgical/trauma patients
  • Early-onset VAP (<5 days): trauma patients prone; aspiration of gastric contents
  • Late-onset VAP (≥5 days): MDR pathogens
Inves
  • Culture-guided
  • Cover gram-positive cocci more common in diabetics, head trauma, ICU
Mng
  • Early broad-spectrum antibiotics in adequate doses; deescalate based on culture
  • Delayed appropriate therapy → increased mortality
  • Empirical (immunocompetent, no MDR risk): ceftriaxone, fluoroquinolone, ampicillin/sulbactam, ertapenem
  • MRSA: linezolid (with emerging linezolid resistance)
  • P. aeruginosa: some isolates only susceptible to polymyxin B
Special
  • VAP partly iatrogenic
  • Early-onset organisms: methicillin-sensitive S. aureus, Streptococcus pneumoniae, Haemophilus influenzae (usually sensitive)
  • Late-onset MDR organisms: MRSA, Pseudomonas aeruginosa, Acinetobacter spp.
  • Common gram-negatives: P. aeruginosa, E. coli, K. pneumoniae, Acinetobacter
  • Anaerobic infection follows aspiration in non-intubated patients; rare in VAP
  • Candida in immunocompetent patient = colonisation, not infection
  • MDR risk factors: hospitalisation ≥5 days; antimicrobials/hospitalisation in prior 90d; nursing home; home infusion; chronic dialysis within 30d; home wound care; family member with MDR pathogen; immunosuppression
  • Pneumonia is 2nd most common nosocomial infection after UTI
31

Post-operative UTI (Catheter-associated)

C/P
  • Most patients harbour infected urine by 5–7 days after surgery (longer catheter = more likely)
  • One of the "4 Ws" of post-op fever ("Water")
Inves
  • Urinalysis: WBC
  • Urine culture: >100,000 bacteria/ml
Mng
  • Treat per culture
  • Catheter removal/change
Special
  • Bacteria crawl up the outside of the urethral catheter
  • Urological instrumentation accelerates the process
  • UTI = most common nosocomial infection overall (35% of HAI in pie chart)
32

Intra-abdominal Infections (IAI)

C/P
  • Uncomplicated (uIAI): contained within a single organ; no GI perforation; rarely causes serious illness
  • Complicated (cIAI): extends beyond source organ into peritoneal cavity via perforated viscus → SIRS
  • Contained spread → abscess; uncontained → diffuse peritonitis → higher mortality, needs urgent celiotomy
  • CA-IAI (community-acquired): lower mortality/morbidity
  • HA-IAI (healthcare-associated): higher mortality/morbidity; resistant pathogens; portends particularly poor prognosis
Inves
  • Imaging to identify source; cultures
Mng
  • CA-IAI: narrow-spectrum, pathogen-specific antimicrobial
  • HA-IAI / high-risk cIAI: broad-spectrum empirical antimicrobial (MDR risk)
  • Source control (e.g., percutaneous drain by interventional radiology for subphrenic abscess; surgical for perforated viscus)
Special
  • Delayed diagnosis triad in HA-IAI: low index of suspicion, poor underlying health, altered sensorium
33

C. difficile Colitis

C/P
  • Frequent stools, abdominal pain, somnolence after recent broad-spectrum antibiotic course
  • Can progress to septic shock with cool skin, hypotension, elevated lactate
Inves
  • Stool testing (implied — deck doesn't enumerate specific tests)
Mng
  • Per institutional protocol; source control
Special
  • Replaces colonic commensals after broad-spectrum antibiotics
  • "Potentially life-threatening diarrhoea in postoperative patients"
  • Classic context: recent antibiotic course (e.g., diverticulitis treatment)

Blood Transfusion Reactions

6 entries
34

Acute Haemolytic Transfusion Reaction (AHTR)

C/P
  • Loin pain, tachycardia, hypotension, fever (e.g., temp rises to 38.9°C ~20 min into transfusion)
  • ABO incompatibility mechanism
Inves
  • Recheck patient ID + blood bag
  • Send component back to lab
  • Blood cultures
  • Monitor temp, pulse, BP, RR, sats (blood gases), urine output
Mng
  • STOP transfusion immediately; keep IV line open with saline
  • Urgent medical review ± ITU
  • Inform blood bank + haematology transfusion registrar
  • May require haemofiltration (ABO incompatibility)
  • Supportive: antibiotics, steroids, adrenaline ± inotropes, bronchodilators, high-flow O₂
Special
  • One of the acute immune transfusion reactions
  • Wrong-blood-in-tube risk 1 in 2,000–4,000; total death risk per component 1 in 125,000; ABO-incompatible red cells 1 in 263,157
  • 50% of reported events due to human error; most serious risks generated at hospital end, not donor end
35

Transfusion-Related Acute Lung Injury (TRALI)

C/P
  • Acute hypoxia + pulmonary infiltrates with no evidence of heart failure
  • Onset within 4 hours of transfusion
  • Life-threatening; 30–50% mortality
  • Not easily distinguished from ARDS
Inves
  • CXR (pulmonary infiltrates)
  • Distinguishing from ARDS is difficult
Mng
  • Supportive (per general severe acute transfusion reaction protocol)
Special
  • Caused by antibodies (often HLA) in transfused product reacting with recipient WBCs (in 50–70% of cases)
  • Leads to pulmonary capillary leakage
  • Implicated donors are often parous women
36

Transfusion-Associated GvHD (TA-GvHD)

C/P
  • Fever, skin rash, pancytopenia, liver failure, renal failure
  • Onset 4 days to 6 weeks post-transfusion
Inves
  • Clinical + lab pattern
Mng
  • Usually fatal (mortality 75–90%); no effective treatment
  • Prevention: irradiated blood components for at-risk recipients
Special
  • Caused by immune reaction of donor T-cells against (often immunodeficient) recipient
  • At-risk indication for irradiated blood: post-BMT, DiGeorge syndrome, Hodgkin lymphoma, certain drugs (fludarabine)
37

Post-Transfusion Purpura (PTP)

C/P
  • Severe thrombocytopenia and bleeding
  • Usually 5–12 days post-transfusion
  • Most often in female patients
Inves
  • Platelet count; platelet-specific alloantibody testing
Mng
Special
  • Platelet-specific alloantibodies → immune-mediated thrombocytopenia
  • Delayed immune transfusion reaction
38

Anaphylactic Transfusion Reaction

C/P
  • Rare but life-threatening
  • Risk higher with blood components containing plasma
Inves
  • Clinical
Mng
  • Per acute transfusion reaction protocol — stop, supportive (adrenaline, steroids, antihistamines)
Special
  • IgE-mediated (occasionally IgG) against allergen
  • IgA-deficient patients can develop anti-IgA antibodies triggering reaction
  • Anaphylactoid reactions = less severe, non-antibody mediated (e.g., donor consumed something recipient is allergic to)
39

Bacterial Contamination / Infective Shock

C/P
  • Onset usually during transfusion of first 100 ml
  • High mortality
Inves
  • Blood culture from patient + component bag
Mng
  • Stop transfusion; per acute transfusion reaction protocol; antibiotics
Special
  • Risk: Platelets >> RBC > FFP (platelets stored at room temp under agitation)
  • Shelf life of platelets only 7 days due to bacterial risk

Respiratory Failure & Acid-Base

7 entries
40

Type 1 Respiratory Failure

C/P
  • Hypoxaemia (PaO₂ <60 mmHg) with normocapnia (PaCO₂ <45 mmHg)
Inves
  • ABG (per definition)
Mng
  • O₂; treat underlying cause
Special
  • Causes listed: pneumonia, ARDS, pulmonary embolus, lactic acidosis
41

Type 2 Respiratory Failure

C/P
  • Hypoxaemia (PaO₂ <60 mmHg) with hypercapnia (PaCO₂ >45 mmHg)
Inves
  • ABG (per definition)
Mng
  • O₂ (cautiously)
  • NIV (BiPAP for ventilation; CPAP for oxygenation/alveolar splinting)
Special
  • Causes listed: opiate toxicity, obstructive sleep apnea, opiate overdose
42

Metabolic Acidosis

C/P
  • ↓ pH, ↓ HCO₃⁻, ↓ CO₂ (with respiratory compensation)
  • Mixed respiratory + metabolic acidosis: ↓ pH, ↑ CO₂, ↓ HCO₃⁻ → cardiac arrest, multi-organ failure in severe sepsis
Inves
  • ABG: base deficit (<-2 mmol/L)
  • Anion gap
Mng
  • Treat underlying cause
Special
  • ROME mnemonic: Respiratory Opposite, Metabolic Equal (pH and CO₂ move in same direction in metabolic disorder)
  • HCO₃⁻ = renal/metabolic contribution to pH control
43

Metabolic Alkalosis

C/P
  • ↑ pH, ↑ HCO₃⁻, ↑ CO₂ (with respiratory compensation)
  • Mixed respiratory + metabolic alkalosis: ↑ pH, ↓ CO₂, ↑ HCO₃⁻ → liver cirrhosis with diuretic use, hyperemesis gravidarum, excessive ventilation in COPD
Inves
  • ABG: base excess (>+2 mmol/L)
Mng
  • Treat underlying cause
Special
44

Respiratory Acidosis

C/P
  • ↓ pH, ↑ CO₂, HCO₃⁻ normal (acute) or ↑ (compensated)
Inves
  • ABG
Mng
  • Treat underlying cause; ventilatory support if needed
Special
  • Causes: respiratory depression (opiates), Guillain-Barré (paralysis), asthma, interstitial lung disease, COPD, iatrogenic (incorrect mechanical ventilation settings)
45

Respiratory Alkalosis

C/P
  • ↑ pH, ↓ CO₂, HCO₃⁻ normal (acute) or ↓ (compensated)
Inves
  • ABG
Mng
  • Treat underlying cause
Special
  • Causes "WASH OUT" (anxiety/panic, pregnancy, early sepsis, mechanical ventilation at excessive rate/volume)
46

Acute Kidney Injury (AKI)

C/P
  • Anuria/oliguria, post-op
  • Urosepsis, urinary tract bleeding
Inves
  • Fluid chart
  • Regular U&E
  • Renal tract ultrasound
  • Urgent urology/nephrology referral
Mng
  • Treat underlying cause; renal replacement therapy if indicated
  • RRT indications: symptomatic uraemia; creatinine >600 µmol/L (6.8 mg/dl); refractory hyperkalaemia; severe acidosis; significant oliguria/anuria; fluid management (overload)
Special
  • Pre-renal: hypovolaemia, hypotension, excessive vasoconstriction (vasopressors)
  • Intrinsic: acute tubular necrosis (drugs/toxins), glomerulonephritis, rhabdomyolysis
  • Post-renal: renal calculi, blocked catheter, neuropathic bladder

Tropical / Parasitic — Bacterial

1 entry
47

Brucellosis (incl. Neurobrucellosis)

C/P
  • Disabling flu-like syndrome with non-specific signs
  • Undulating ("undulant") fever, sweating, chills, myalgia, arthralgia, fatigue
  • Also known as: remitting/relapsing fever, undulant fever, Mediterranean fever
  • Common symptoms: headache, cyclical fever, migratory arthralgia, myalgia, asthenia, anorexia, fatigue, malaise, weakness, sweating, vomiting, diarrhoea, abdominal pain, miscarriage
  • Physical: may be normal; lymphadenopathy, splenomegaly, hepatomegaly
  • Skin lesions: maculopapular eruptions, erythema nodosum, abscesses
  • Ocular: uveitis, keratoconjunctivitis, iridocyclitis, optic neuritis, cataracts
  • Neurological (neurobrucellosis): meningitis (nuchal rigidity, Kernig, Brudzinski), papilloedema, cranial nerve palsy, focal neurological deficits
  • Complications (rare if treated <1 month from symptom onset):
    • Cardiovascular: endocarditis (new/changing murmurs), myocarditis, pericarditis (rub)
    • Genitourinary: orchitis, epididymo-orchitis, glomerulonephritis, pyelonephritis, abortion
    • CNS: meningitis, meningoencephalitis, papilledema, stroke, optic neuropathy
    • Haematologic: DIC
    • Musculoskeletal: sacroiliitis, arthritis, osteomyelitis, tenosynovitis
    • GI/Hepatobiliary: hepatitis, hepatic abscess, acute cholecystitis, ileitis, colitis; abscess in spinal cord, spleen, thyroid
Inves
  • Dietary + occupational history essential
  • CBC: neutropenia + anaemia; thrombocytopenia (hepatosplenomegaly or immune)
  • Raised ESR, CRP, LDH
  • Elevated ALT, AST, ALK PHOS
  • Culture (gold standard): blood culture in tryptose medium + BACTEC system; slow-growing ≥1 week; sensitivity 10–90%
  • Bone marrow culture: higher yield than blood (RES concentration)
  • Serology (most practical): Standard Agglutination Test (SAT); indirect ELISA; repeat if initial titre low
    • Titre >1:160 + compatible clinical picture → suggestive of infection
    • Titre >1:320 → more specific (esp. endemic areas)
  • PCR / NAAT: rapid, species-specific
  • Radiography (spondylitis): disc space narrowing, bone destruction, sclerosis
  • Bone marrow aspiration/biopsy: in selected patients
  • Percutaneous liver biopsy: for liver granulomas — granulomatous hepatitis, hepatic microabscesses
  • Neurobrucellosis: CSF — lymphocytes, low glucose, elevated protein (aseptic meningitis pattern); Brucella antibodies in CSF; SAT positive
Mng
  • Doxycycline + (streptomycin OR rifampin OR gentamicin) OR sulfamethoxazole/trimethoprim
  • Several weeks needed (intracellular organism)
  • Avoid single-agent therapy (high relapse)
  • Uncomplicated: doxycycline 100 mg PO BD × 6 weeks; monotherapy relapse ≈40% so usually + rifampin 600–900 mg/day
  • Fluoroquinolones = secondary alternatives
  • Pregnancy: rifampin during pregnancy; trimethoprim–sulfamethoxazole added postpartum
  • Spondylitis / sacroiliitis: doxycycline + rifampin + aminoglycoside (gentamicin) × 2–3 weeks initial, then 6 weeks rifampin + doxycycline
  • Symptomatic: antipyretics + analgesics
  • Surgery: endocarditis (valve replacement); drainage of pyogenic joint effusion/paraspinal abscess; debridement + bone grafting for spondylitis
  • Mostly outpatient unless complicated
  • Avoid contact with source
  • Serological monitoring during treatment
  • Compliance essential
Prevention
  • Avoid infected animals; gloves + masks; avoid contaminated food
  • Adequate cooking of meat; pasteurisation of dairy
  • Lab containment
  • Livestock vaccination (most efficient approach)
  • No human vaccine available
Special
  • Endemic zoonotic disease (cattle, dogs, sheep, goats)
  • Gram-negative aerobic coccobacillus; does NOT form spores or toxins
  • 4 human pathogenic species: B. melitensis (sheep, most virulent), B. suis (pigs, next), B. abortus (cattle), B. canis (dogs)
  • Bacteria in animal reproductive organs → abortions and sterility; shed in urine, milk, placental fluid
  • Transmission: direct animal contact; raw/unpasteurised dairy; inhalation in slaughterhouse/meat processing; butchers, lab workers high risk
  • Lacks classical virulence factors; pathogenesis via host cell invasion, immune evasion, chronic infection within macrophages
  • Incubation 3 days to several weeks
  • Relapse 5–15% within 6–12 months of completing therapy
  • Recovery 3–6 months
  • Overall mortality <2%
  • Poor prognosis with CHF due to endocarditis
  • Improves with physical activity rather than bed rest

Tropical / Parasitic — Protozoal

1 entry
48

Malaria

C/P
  • Initial symptoms non-specific: tachycardia, tachypnea, chills, malaise, fatigue, diaphoresis, headache, cough, anorexia, nausea, vomiting, abdominal pain, diarrhoea, arthralgia, myalgia
  • Physical: anaemia + palpable spleen
  • Mild jaundice may develop in uncomplicated falciparum
  • Febrile paroxysms at irregular intervals; temp can rise >40°C with tachycardia/delirium; cyclic 2–3 days
  • Febrile convulsions in children (any species); generalised seizures associated with falciparum (may herald cerebral malaria)
  • Severe malaria: altered consciousness ± seizures; respiratory distress or ARDS; circulatory collapse; metabolic acidosis; renal failure with haemoglobinuria ("blackwater fever"); hepatic failure; coagulopathy ± DIC; severe anaemia or massive intravascular haemolysis; hypoglycaemia
  • Pallor, petechiae, jaundice, hepatomegaly, splenomegaly (splenic rupture described)
  • Cerebral malaria: encephalopathy with impaired consciousness, delirium, ± seizures; focal neurological signs unusual; onset gradual or sudden following a convulsion
Inves
  • Suspect in any febrile illness with exposure to endemic region
  • Light microscopy (standard tool): Giemsa-stained blood smears
    • Thin smear: erythrocyte morphology preserved; parasites visible within RBCs; for species ID + parasite density
    • Thick smear: mechanical lysis of RBCs; reviews large blood quantity; for presence/absence screening + density estimation
  • Rapid diagnostic tests (RDTs): detect parasite antigens (HRP2, pLDH, aldolase); 15–20 min; resource-limited settings; qualitative only; can distinguish P. falciparum vs P. vivax depending on antigen
  • PCR (molecular): gold standard in efficacy studies; reference labs only
  • Uncomplicated parasitemia: <5,000 parasites/µL (<0.1% RBCs); anaemia, thrombocytopenia, elevated transaminases, mild coagulopathy, raised BUN + creatinine
  • Severe: parasitemia ≥4–10%; increasing parasitemia → increasing severity
  • Cerebral malaria: CSF normal or slightly elevated protein/cell count; retinal haemorrhages 30–40% (pupillary dilation + indirect ophthalmoscopy)
Mng
  • Inform patients of recrudescence; report to state health department
  • Identify chloroquine-sensitive vs resistant area
  • Uncomplicated, chloroquine sensitive: chloroquine monotherapy
  • Uncomplicated, chloroquine resistant: combination of two agents (ACTs)
  • Hospitalisation indications: clinical observation for tolerance; young children; immunocompromised; no acquired immunity (travellers); hyperparasitemia 4–10% without severe signs
  • Severe malaria — parenteral artemisinin:
    • Artesunate IV/IM 2.4 mg/kg at 0, 12, 24, 48h
    • OR artemether IM 3.2 mg/kg stat then 1.6 mg/kg OD
    • Follow-up: ACT + primaquine (0.75 mg/kg on day 2)
    • If artemisinin unavailable: quinine salt 20 mg/kg infusion then 10 mg/kg Q8H; follow-up quinine 10 mg/kg Q8H PLUS doxycycline 100 mg OD OR clindamycin 10 mg/kg BD × 7 days (clindamycin in pregnancy / child <8)
Traveller Chemoprevention
  • Low risk/sporadic: mosquito avoidance only
  • Chloroquine-resistant P. falciparum: mosquito avoidance + atovaquone-proguanil OR mefloquine OR doxycycline OR tafenoquine
  • Chloroquine-sensitive P. falciparum: chloroquine OR atovaquone-proguanil/tafenoquine (mefloquine, doxycycline also effective)
  • P. vivax dominant (Mexico / Central America): primaquine OR tafenoquine (check G6PD); chloroquine also effective
  • Long-term use evidence supports atovaquone-proguanil, chloroquine, doxycycline, mefloquine for up to 2 years
  • Timing: start before travel, continue during, and for a period after departure
Special
  • Plasmodium parasite; female Anopheles mosquito vector (bites dusk–dawn)
  • P. falciparum = largest burden (sub-Saharan Africa, New Guinea, Hispaniola)
  • P. vivax: Americas, western Pacific
  • Lifecycle: bite → sporozoites travel to liver → mature → enter blood → infect RBCs (multiply 48–72h) → burst at ~2 weeks releasing merozoites (cause fever) → cyclic 2–3 days
  • Severe pathophysiology: cytoadherence of parasitised (+ non-parasitised) RBCs to small vessels → micro-infarcts, capillary leakage, organ dysfunction
  • Cerebral malaria untreated = almost universally fatal; treated mortality 15–20%
  • Risk factors for cerebral malaria: extremes of age, pregnancy, poor nutrition, HIV, genetics, splenectomy
  • Differentials:
    • Dengue: myalgia more severe ("breakbone fever") — serology
    • Chikungunya: dengue-like but milder/self-limiting with rash — serology
    • Meningitis: no neck stiffness/photophobia in malaria; malaria has no rash
    • Typhoid: bradycardia, abdominal pain, rose spots — stool/blood culture
    • Leptospirosis: more severe myalgia + petechial haemorrhages (rare in malaria)
    • Viral haemorrhagic fever: petechial haemorrhages common

Tropical / Parasitic — Helminthic

11 entries
49

Schistosomiasis (Bilharziasis)

C/P
  • Acute (Katayama fever / "swimmer itch"): sudden fever, urticaria + angioedema, chills, myalgias, arthralgias, dry cough, diarrhoea, abdominal pain, headache; 4–8 weeks post-infection
  • Chronic: months to years post-infection
    • S. mansoni: hepatosplenomegaly + periportal fibrosis → enlarged liver/spleen → portal vein occlusion → portal hypertension with splenomegaly → portocaval shunting → GI varices
    • S. haematobium: sandy patches in urinary bladder, haematuria, bladder cancer
Inves
  • Stool / urine microscopy for eggs (implied — deck focuses on chronic features)
Mng
  • Praziquantel 20 mg/kg given immediately
  • Repeated once 4–6 hours later
  • Children >4 years and adults
Special
  • Infection with parasitic blood flukes; bisexual flukes (only flukes with separate sexes infecting humans)
  • 5 species: S. mansoni, S. haematobium, S. japonicum, S. intercalatum, S. mekongi
  • Lifecycle: eggs in faeces/urine/sputum → aquatic environment → miracidia → snail intermediate host → cercariae → penetrate definitive host (skin)
  • Prevention: avoid freshwater in endemic areas (Caribbean, S. America, Africa, Asia)
50

Enterobiasis (Pinworm)

C/P
  • Cardinal symptom: pruritus ani (perianal itch)
  • Most common helminthic infection in Western Europe
Inves
  • Clinical (implied; deck doesn't detail)
Mng
  • Mebendazole 100 mg immediate dose, then repeated
  • Treat the whole family on first occasion
  • Re-infection prevention: avoid scratching; scrub under fingernails; boil-wash or hot-iron bedding + clothing to kill eggs
Special
  • Enterobius vermicularis (pinworm / threadworm)
  • Gravid worms deposit eggs in perianal folds
  • Auto-infection by scratching → hand-to-mouth
  • Person-to-person via contaminated surfaces or food
51

Trichuriasis (Whipworm)

C/P
  • Most patients asymptomatic
  • Heavy infestation: severe GI symptoms — colitis, dysentery
  • Children: iron deficiency anaemia, growth retardation; rarely rectal prolapse from severe dysentery
Inves
  • Stool microscopy
  • FBC: eosinophilia likely
Mng
  • Albendazole 400 mg BD × 3 days (unlicensed)
  • Mebendazole 500 mg single dose (adults)
  • Mebendazole 100 mg BD × 3 days (children 1–18y)
Special
  • Trichuris trichiura (whipworm)
  • Direct nematode infection (anus → mouth, no soil)
52

Ascariasis

C/P
  • SOB, cough, abdominal pain, intestinal blockage, impaired growth
Inves
  • Microscopic stool exam; imaging
Mng
  • Self-limiting with sanitation
  • Albendazole / Mebendazole if needed
Special
  • Ascaris lumbricoides — "modified direct" nematode (faecal eggs need soil incubation)
  • Transmission: eggs in faecally contaminated food/water
53

Hookworm

C/P
  • Cough, itchy rash, abdominal pain, diarrhoea, anaemia, fatigue, impaired growth
Inves
  • Microscopic observation of eggs in stool
Mng
  • Albendazole, Mebendazole
  • Prevention: wear shoes
Special
  • Ancylostoma duodenale, Necator americanus
  • Skin-penetration nematode (larvae in soil → bare feet)
54

Strongyloidiasis

C/P
  • Often asymptomatic
  • Cough ± bloody, rash, abdominal pain, diarrhoea
  • Immunosuppressed → dissemination and fatal complications
Inves
  • Larvae in stool (microscopy)
  • Serology for antigens
Mng
  • Ivermectin (preferred)
  • Albendazole
Special
  • Strongyloides stercoralis
  • Soil-dwelling larvae penetrate skin (bare feet)
55

Trichinosis

C/P
  • Diarrhoea, abdominal cramps, fever, myalgia, headache
  • Severe → impaired coordination, breathing, heart function
Inves
  • Cysts in muscle biopsy
  • Immunoassays
Mng
  • Albendazole, Mebendazole
Special
  • Trichinella spiralis
  • From raw/undercooked pork or other meat
56

Taeniasis (Intestinal Tapeworms)

C/P
  • Asymptomatic or mild GI distress
  • Cysts in muscle / eye / brain (neurocysticercosis): headaches, seizures, death
Inves
  • Proglottids or eggs in stool
  • CT/MRI for cysts
Mng
  • Praziquantel, Niclosamide
Special
  • Taenia solium, T. saginata, Diphyllobothrium latum
  • Transmission: raw/undercooked beef or pork with larvae
57

Cysticercosis

C/P
  • Cysts in lungs, liver, brain, other tissues
  • Seizures, meningitis, hydrocephalus
Inves
  • CT or MRI to detect cysts
Mng
  • Surgical removal if accessible
  • Albendazole, Praziquantel
Special
  • Taenia solium larval cysts (egg exposure via faecally contaminated food/water — distinct from taeniasis which is larvae in meat)
58

Liver Fluke Infections

C/P
  • Often asymptomatic
  • Chronic: abdominal pain, cholangitis, gallstones
Inves
  • Microscopic eggs in stool
Mng
  • Praziquantel
Special
  • Clonorchis sinensis, Opisthorchis spp.
  • Transmission: raw/undercooked freshwater fish
59

Fascioliasis

C/P
  • Diarrhoea, abdominal pain, hepatomegaly, allergic reactions
Inves
  • Microscopic eggs in stool
Mng
  • Praziquantel
Special
  • Fasciola hepatica (classed as intestinal fluke in deck)
  • Transmission: raw/undercooked aquatic plants with cysts

Rheumatic / Autoimmune

3 entries
60

Rheumatoid Arthritis

C/P
  • Affects 1% of population (higher >50y)
  • Female:Male = 3:1
  • Onset typically 20–50y
  • Joint destruction → deformity → disability
  • Life expectancy shortened
Inves
  • Rheumatoid Factor (RF): antibodies to IgG; sensitivity >80% in RA at high levels; IgA and IgM RF present years before onset; most RF are IgM subtype; high levels = worse prognosis
  • Anti-CCP (anti-cyclic citrullinated peptide): as sensitive as and more specific than IgM RF in early + established disease; predicts development into RA in undifferentiated arthritis; marker of erosive disease; detectable in healthy individuals years before clinical RA
Mng
  • — (deck doesn't enumerate RA-specific drugs; TNF role implicated as pivotal cytokine for biologic therapy)
Special
  • Pathogenesis: abnormal antigen presentation in synovium; immune complex–mediated; T cell + macrophage dysregulation → MMP + RANKL ligand production
  • TNF = pivotal (but not exclusive) cytokine; acts pro- and anti-inflammatory directly + indirectly via IL-1, IL-6
  • Citrullinated extracellular fibrin in synovium = major autoantigen; citrullination by PAD (peptidylarginine deiminase)
  • Plasma cells make RF antibodies in the joint
  • Major synovial cell types: T lymphocytes, macrophage-like (type A) synoviocytes, fibroblastic (type B) synoviocytes; less abundant — dendritic cells, B cells, plasma cells, mast cells, osteoclasts
61

Systemic Lupus Erythematosus (SLE)

C/P
ACR 1982 criteria — ≥4 of 11
  • Malar rash: fixed red rash over cheeks
  • Discoid rash: red patches with scaling + plugging of hair follicles
  • Photosensitivity: rash after sunlight exposure
  • Mucosal ulcers: mouth and nose
  • Serositis: inflammation of delicate tissues covering internal organs; abdominal pain
  • Arthritis: very common; joint pain
  • Renal disorder: detected by routine blood + urine analysis
  • Neurological disorder: seizures or psychosis
  • Haematological disorder: haemolytic anaemia, leukopenia, thrombocytopenia
  • Immunologic disorder: LE cells, anti-DNA, anti-Sm antibodies
  • ANA positive (not on offending drugs)
Inves
  • ANA by indirect immunofluorescence (IIF): patterns include homogenous/speckled, high titre
  • Anti-dsDNA: screen with Crithidia luciliae; monitoring by quantitative ELISA
  • Direct immunofluorescence (DIF): immune complex deposition in skin + kidney (anti-IgG or C3 antibody with fluorescent probe)
  • Limitations: ANA can be positive in healthy individuals (esp. elderly); positive ANA in non-CTD has no diagnostic/prognostic value; ANA titre ≠ disease activity
Mng
  • Rituximab (chimeric monoclonal anti-CD20 antibody) → B-cell depletion lasting 6–9 months; response rate ~60%
    • Antibody levels that fall: anti-DNA, anti-nucleosome, anti-C1q, anti-cardiolipin
    • Antibody levels that do NOT fall: anti-Ro, anti-La, anti-Sm, anti-RNP, anti-measles, anti-tetanus toxoid
Special
  • Predominantly women of childbearing age
  • Environmental factors (anecdotal/suggested): sunlight, pesticides, silica, mercury, EBV infection, hormones
  • Paradox: ~90% of adults are EBV-infected, yet SLE prevalence remains low → multifactorial pathogenesis
  • SELENA study: HRT → increase in mild flare but no overall increase in disease activity
  • Immunopathogenesis: genetic susceptibility + external triggers → B and T cells specific for self-nuclear antigens (failure of self-tolerance) → apoptosis with defective clearance → TLR stimulation of B cells + DCs by antigen-antibody complexes → type I IFN (IFN-α) production → persistent IgG anti-nuclear antibodies
  • Discoid lupus: imaging shown pre/post B-cell depletion in deck
62

Systemic Sclerosis (Scleroderma)

C/P
  • Diffuse, progressive scleroderma: generalised skin thickening with rapidly progressive and often fatal visceral involvement
  • Limited cutaneous scleroderma (CREST syndrome):
    • Calcinosis cutis
    • Raynaud's syndrome
    • Esophageal dysmotility
    • Sclerodactyly
    • Telangiectasias
  • Skin thickening most obvious; also affects kidney, lung, heart, gut
Inves
  • ANA testing useful in CTD work-up (per general autoimmune section)
Mng
Special
  • Systemic disease characterised by sclerosis of connective tissue

Sepsis & Infection

7 entries
1

Sepsis 1 vs Sepsis 3 Definitions

Use: Classify infection-related illness severity.

Sepsis 1 (1991) — classical spectrum
  • Sepsis = identifiable source of infection + SIRS
  • Severe sepsis = sepsis + organ dysfunction
  • Septic shock = sepsis + cardiovascular collapse (requiring vasopressor support)
Sepsis 3 (2016) — new definition
  • Sepsis = life-threatening organ dysfunction caused by a dysregulated host response to infection
  • Septic shock = vasopressors needed for MAP >65 mmHg + lactate >2.0 mmol/L despite adequate fluid resuscitation
  • Abandoned: SIRS criteria for identifying sepsis; "severe sepsis" term
2

SIRS Criteria (Sepsis 1)

Use: Identify systemic inflammatory response. ≥2 criteria required.

  • Temperature: ≥38°C or ≤36°C
  • Heart rate: ≥90 bpm
  • Respiratory rate: ≥20/min OR PaCO₂ ≤32 mmHg (or mechanical ventilation)
  • WBC: ≥12,000/µL OR ≤4,000/µL OR ≥10% band forms
3

qSOFA Score

Use: Bedside screening tool to identify patients at risk of poor outcome from infection. Score ≥2 → start sepsis care pathway.

  • Respiratory rate >22/min
  • Altered mental status
  • Systolic BP <100 mmHg

Limitation: Poor sensitivity — likely excludes its use as an early sepsis screening tool on its own.

4

SOFA Score

Use: Predicts mortality risk for ICU patients based on lab and clinical data. A score of ≥2 is associated with a 10% or greater increase in mortality.

SystemParameter
RespiratoryPO₂ / FiO₂
CoagulationPlatelets / mm³
LiverBilirubin (mg/dl)
CardiovascularMAP and requirement for vasopressors (Dopamine, Epinephrine, Norepinephrine)
CNSGlasgow Coma Scale
RenalCreatinine (mg/dl) and Urine output (ml/d)
5

Sepsis Six Bundle

Use: Within the first hour of sepsis recognition. Key stat: 7.6% mortality increase for every hour delay in giving antibiotics.

  • Supplemental Oxygen (high flow 15 L/min via non-rebreathe, target sats >94%)
  • Establish IV access and start crystalloid (30 ml/kg)
  • Insert a urinary catheter (hourly output monitoring)
  • Draw a blood culture before starting antibiotics
  • Administer empirical antibiotics
  • Determine a lactate level

Ensure Hb >7 g/dl. Consider vasopressors if hypotensive after fluid resuscitation. Control the source of sepsis.

6

Surviving Sepsis Campaign Bundles (2012)

Within 3 hours
  • Measure lactate level
  • Obtain blood cultures prior to administration of antibiotics
  • Administer broad-spectrum antibiotics
  • Administer 30 ml/kg crystalloid for hypotension or lactate ≥4 mmol/L
Within 6 hours
  • Apply vasopressors (for hypotension that does not respond to initial fluid resuscitation) to maintain MAP ≥65 mmHg
  • In persistent hypotension despite volume resuscitation or initial lactate ≥4 mmol/L: measure CVP and central venous oxygen saturation (ScvO₂)
  • Remeasure lactate if initial lactate was elevated
Quantitative resuscitation targets
  • CVP ≥8 mmHg
  • MAP ≥65 mmHg
  • Urine output ≥0.5 ml/kg/h
  • ScvO₂ ≥70%
  • Normalisation of lactate
7

LRINEC Score (NSTI)

Use: Supports clinical suspicion of necrotising soft tissue infection. Score ≥6 → high suspicion (PPV 92%, NPV 96%).

6 variables
  • Total WBC count
  • Haemoglobin
  • Sodium
  • Glucose
  • Serum creatinine
  • C-reactive protein
Suggestive lab thresholds
  • WBC ≥15,400/µL
  • Serum sodium <135 mEq/L

Limitation: Failed to distinguish those with or without septic shock/death — should not be solely relied on for diagnosis.

Trauma & Shock

4 entries
8

ATLS Haemorrhage Classification (4-Stage)

Use: Classify severity of haemorrhagic shock by physiological parameters.

ParamStage 1Stage 2Stage 3Stage 4
% Blood loss<15%15–30%30–40%>40%
Cap refill<2s>2s5s>5s
PeripheriesWarmCoolColderColdest
Heart rate<100>100>120>140
Blood pressureNormalNormal or narrow pulse pressureLowVery low
Resp rate14–2020–3030–40>35
Urine output (ml/hr)>3020–305–15Negligible
ConsciousnessSlightly anxiousAgitatedConfused/lethargicUnresponsive

Compensation sequence: peripheral vasoconstriction → tachycardia → postural hypotension → recumbent hypotension

BP is the LAST parameter to drop — normal BP does NOT rule out significant blood loss.

9

Major Haemorrhage Protocol Triggers

Use: Activate massive transfusion protocol (e.g., dial 2222). Communication via SBAR. Nominate a coordinator/scribe.

  • Replacement of entire blood volume in 24 hours
  • Total transfusion >8–10 packed RBC units in 24 hours
  • Replacement >50% blood volume in 3 hours
  • Blood loss ≥150 ml/min
  • Transfusion of ≥4 RBC units in 1 hour with ongoing haemorrhage
  • Patient predicted to need ≥8 packed RBC units within 2 hours

Component ratio PRBC : FFP : Platelets = 1:1:1. Use permissive hypotension. Don't over-fluid (dilutes coagulation factors).

TXA (Tranexamic Acid): 1g bolus over 10 min then 1g infusion over 8h. Every 15-min delay decreases survival by 10%.

10

ABCDE Primary Survey

Use: Vertical approach for trauma resuscitation. For multiple trauma patients, use a horizontal approach (simultaneous, team-based task execution with delegated roles).

  • A — Airway
  • B — Breathing
  • C — Circulation
  • D — Disability (neurological assessment — GCS, pupils, lateralising signs, blood glucose)
  • E — Exposure / Environment (remove clothing, logroll, prevent hypothermia, keep dignity, remove spine board ASAP)

Adjuncts: e-FAST, CXR, PXR, ± lateral cervical spine, ± whole-body CT, ± angiography/IR; analgesia (pharmacological, psychological, physical).

Planning round (STOP): all life-threats identified? all investigations done? analgesia given? what is the Plan? non-essential team disbanded? relatives informed?

11

AMPLE History (Secondary Survey)

Use: Concise medical history during trauma secondary survey, performed only when all immediately life-threatening conditions have been treated.

  • A — Allergies
  • M — Medications
  • P — Past medical history
  • L — Last meal
  • E — Events leading to presentation

Pre-op Assessment

8 entries
12

NCEPOD Classification of Intervention Urgency

Use: Classify timing of surgical intervention. NCEPOD = National Confidential Enquiry into Patient Outcome and Death.

ClassDefinition & timingExample
ImmediateLife/limb/organ saving; resuscitation simultaneous with surgery; within minutesRapid bleeding (trauma, aneurysm)
UrgentLife/limb/organ threatening; within hoursPerforated bowel or less urgent bleeding
ExpeditedEarly surgery within a day or twoLarge bowel obstruction, closed long bone fracture
ElectiveTiming to suit patient and hospitalJoint replacement, unobstructed hernia repair, cataract
13

ASA Classification & Mortality

Use: American Society of Anesthesiologists physical status classification.

ClassDefinitionMortality
IA normally healthy patient0.05%
IIMild systemic disease, not limiting activity0.4%
IIISevere systemic disease that limits activity but not incapacitating4.5%
IVIncapacitating systemic disease, constant threat to life25%
VMoribund; not expected to survive 24h with or without operation50%
14

POSSUM Score

Use: Risk stratification for surgical patients. POSSUM = Physiological and Operative Severity Score for the enUmeration of Mortality and Morbidity.

Composition: 12 physiological + 6 operative parameters.

12 physiological parameters
  • Age, cardiac, respiratory, ECG, systolic BP, pulse rate, haemoglobin, WBC, urea, sodium, potassium, GCS
6 operative parameters
  • Operation type, number of procedures, operative blood loss, peritoneal contamination, malignancy status, CEPOD (timing)
15

Mallampati Classification

Use: Airway assessment based on visible oropharyngeal structures.

ClassVisible structures
IUvula, fauces, soft palate, pillars visible
IIUvula, soft palate, fauces visible
IIIBase of uvula visible; soft palate visible
IVOnly hard palate visible

Three axes to align for intubation: oral, pharyngeal, laryngeal. Mr Douglas airway-difficulty factors: rheumatoid arthritis; cervical spine surgery; limited mouth opening.

16

Preoperative Airway Score (7 Criteria)

Use: Predict difficulty of intubation. Score range 0–14 (higher = greater predicted difficulty).

Criterion0 pts1 pt2 pts
Interincisor gap>4 cm4 cmCannot open mouth
MallampatiClass IClass IIClass III
Head/neck movement>90°=90°<90°
Buck teethCan prognath or edentulousCan approximate teeth onlyCannot approximate teeth
Thyromental distance>6.5 cm6.0–6.5 cm<6.0 cm
Body weight<90 kg90–110 kg>110 kg
Difficult intubation hxNoneQuestionableDefinite
17

Functional Capacity Assessment

Use: Predict perioperative cardiac risk. Strong predictor.

  • Walking endurance: Can the patient walk a mile?
  • Stair tolerance: Can they climb a flight of stairs?
  • Day-to-day function: Activities of daily living
  • Severity & stability of comorbidities; current medications; previous surgery & anaesthetics (problems? family history?)
18

Preoperative Fasting Times

Intake typeMinimum fasting
Clear liquids (water, clear tea, black coffee, carbonated, fruit juice w/o pulp)2 h
Breast milk4 h
Non-human milk / light meal (infant formula; toast + clear liquids)6 h
Regular or heavy meal (fried/fatty food, meat)8 h
19

Preoperative Preparation Steps

  • Correct the correctable (low Hb, low potassium, high INR)
  • Stabilise/improve medical co-morbidities
  • Explain & sign informed consent
  • Premedication (as appropriate)
  • Cross match & save blood
  • Antibiotic & DVT prophylaxis
  • Check for LATEX allergy

Medication rule: Continue preoperative medications. Exceptions: insulin; oral hypoglycaemics; ACE inhibitors (sometimes); anti-coagulants.

Hip fracture timeframe: Standard time-to-fix = 48 hours. Risks of delay >48h: DVT, pneumonia. Specialist consultation: cardiologist & pulmonologist (goal: optimise).

Surgical Safety

3 entries
20

WHO Surgical Safety Checklist (3 Phases)

  • Sign In (before induction): identity, site, consent, pulse ox, allergies, airway risk
  • Time Out (before skin incision): team intro; antibiotic prophylaxis (<60 min); critical events anticipated
  • Sign Out (before patient leaves): instrument/needle counts; specimen labelling
21

Enhanced Recovery After Surgery (ERAS)

Goal: Reduce surgical stress to retain anabolic homeostasis.

Key elements
  • Carbohydrate drinks 2 hours before surgery (replaces overnight fasting)
  • Minimally invasive approaches
  • Fluid management (balance vs large volumes)
  • Early removal of drains/tubes
  • Early mobilisation
  • Serving drinks/food day of operation
Outcomes
  • Shorter hospital stay (30–50%)
  • Reduced complications
  • Reduced cost
22

SSI Prevention Bundle

  • Antimicrobial prophylaxis — 5 sub-elements: name; timing; weight-based dose; re-dosing; discontinuation
  • Skin antisepsis — standardised peri-operative practices
  • Temperature control — normothermia maintenance
  • Glycaemic control — glucose control optimisation
  • Oxygenation — supplemental oxygen
  • MRSA — screening/decolonisation
  • Aseptic measures — traffic control; attire; audit

Pain & Sedation

4 entries
23

WHO Analgesic Ladder

  • Step 1: Non-opioid ± adjuvant
  • Step 2: Opioid for mild to moderate pain ± non-opioid ± adjuvant
  • Step 3: Opioid for moderate to severe pain ± non-opioid ± adjuvant

Golden Rule: Treat the PATIENT, not the number.

24

SOCRATES (Pain History Mnemonic)

  • S — Site
  • O — Onset (sudden/gradual)
  • C — Character
  • R — Radiation
  • A — Associations
  • T — Time course (pattern)
  • E — Exacerbating/Relieving factors
  • S — Severity
25

FLACC Scale (Paediatric / Non-verbal)

Use: Pain assessment in children or non-verbal patients. Total score 0–10 (Merkel et al, 1997).

CategoryScore 0Score 1Score 2
FaceNo particular expression or smileOccasional grimace or frown, withdrawnFrequent/constant frown, quivering chin, clenched jaw
LegsNormal position or relaxedUneasy, restless, tenseKicking or legs drawn up
ActivityLying quietly, normal position, moves easilySquirming, shifting back and forth, tenseArched, rigid, or jerking
CryNo cry (awake or asleep)Moans or whimpers; occasional complaintCrying steadily, screams or sobs, frequent complaints
ConsolabilityContent, relaxedReassured by touching, hugging, talking; distractibleDifficult to console or comfort
26

Pain Assessment Tools

Frequency: Every time vital signs are taken.

Physiological
  • Autonomic (BP, HR, RR), cortical level
Patient reporting
  • Verbal: "mild" / "moderate" / "severe"
  • Visual Analogue Scale (10 cm line)
  • Verbal Numerical Rating Scale (0–10)
  • Wong-Baker FACES: 0 (No Hurt) to 10 (Hurts Worst)
Protocol
  • Assess — Treat — Reassess — Escalate

Post-op

3 entries
27

4 Ws of Post-op Fever

Use: Systematic check for principal sources of postoperative fever. Fever = temperature >38°C (occurs in ~40% of post-op patients).

  • Wind — atelectasis or pneumonia
  • Water — urinary tract infection
  • Walk — thrombophlebitis
  • Wound — wound infection
Work-up
  • Look at surgical incisions
  • Look at IV sites for septic thrombophlebitis
  • Order blood/urine/sputum cultures
  • Obtain chest X-ray if breath sounds worrisome

Early causes (1–3 days): atelectasis (traditional). Late causes (~2 weeks): septic thrombophlebitis (from IV line); occult intra-abdominal abscesses.

28

PINCH ME (Delirium Causes)

Use: Mnemonic for correctable causes of postoperative delirium. Postop delirium ~50% of cases (especially elderly + orthopaedic surgery).

  • P — Pain
  • IN — Infection
  • C — Constipation
  • H — Dehydration
  • M — Medications
  • E — Environment

Other causes to consider: electrolyte disturbance, hypo/hyperglycaemia, acid-base disturbance, organ failure, sedatives, hypoxia or hypercapnia.

29

Tetanus Prophylaxis Algorithm

Tetanus-prone wound criteria (any of)
  • Sustained >6 hours before surgery
  • Significant devitalised tissue
  • Puncture injury
  • Contact with soil/manure
  • Associated clinical sepsis, foreign body, or compound fracture
Management by vaccine status
Vaccine statusWound typeAction
Up to dateStandardNo further vaccine
Up to dateHigh risk (e.g., manure)+ Human tetanus immunoglobulin
Not up to dateTetanus-proneReinforcing Td/IPV + Immunoglobulin
Not up to dateNon-proneReinforcing Td/IPV only (or start course)
Immunoglobulin dose
  • Standard: 250 IU IM
  • High risk / >24h elapsed / heavy contamination / burns: 500 IU

Acid-Base

2 entries
30

ROME (Acid-Base Direction Mnemonic)

Use: Determine whether the primary acid-base problem is respiratory or metabolic.

  • Respiratory Opposite — pH and CO₂ move in opposite directions
  • Metabolic Equal — pH and CO₂ move in the same direction
DisorderpHCO₂HCO₃
Respiratory acidosisNormal
Respiratory alkalosisNormal
Resp acidosis + metabolic compensation↓ / ↔
Resp alkalosis + metabolic compensation↑ / ↔

Compensation always goes in the same direction as the primary problem. CO₂ is an acid. Remember: ABG steps = Oxygenation → pH → pCO₂ → HCO₃ → Compensation → Anion Gap.

31

Respiratory Alkalosis Causes (WASH OUT)

Use: Common causes of respiratory alkalosis.

  • Anxiety / panic (including panic attacks)
  • Pregnancy
  • Early sepsis
  • Mechanical ventilation at excessive rate or volumes

Autoimmune & Nutrition

2 entries
32

ACR 1982 SLE Criteria

Use: Diagnose SLE. Patient must have ≥4 of these 11 manifestations at any time since disease onset.

  • Malar rash: fixed red rash over the cheeks
  • Discoid rash: red patches with scaling and plugging of hair follicles
  • Photosensitivity: rash after sunlight exposure
  • Mucosal ulcers: small sores in mouth and nose
  • Serositis: inflammation of delicate tissues covering internal organs; abdominal pain
  • Arthritis: very common; pain in the joints
  • Renal disorder: usually detected by routine blood and urine analysis
  • Neurological disorder: seizures or psychosis
  • Haematological disorder: haemolytic anaemia, leukopenia, thrombocytopenia
  • Immunologic disorder: tests on LE cells, anti-DNA, and anti-Sm antibodies
  • Anti-Nuclear Antibody (ANA): positive (when patient is not taking drugs known to cause a positive test)
33

Nutritional Severity Score

Impaired nutritional status (short-term = food intake in last week)
  • Score 1: Decreased within 50–70% of normal requirements
  • Score 2: 25–60% of normal requirements
  • Score 3: 0–25% of normal requirements
Impaired nutritional status (longer-term = weight loss & BMI changes)
  • Score 1: >5% weight loss in 3 months
  • Score 2: >5% in 2 months · BMI 18.5–25 · impaired general condition
  • Score 3: >5% in 1 month · BMI <18.5 · impaired general condition
Severity of disease
  • Score 1: Diabetes; oncology; chronic patients (COPD or cirrhosis) with acute complications; chronic haemodialysis; hip fractures
  • Score 2: Major surgery; stroke; severe pneumonia; haematological malignancy
  • Score 3: ICU patients; head injury; bone marrow transplantation
Scoring rules & management
  • Age adjustment: if age >70, add 1 to give "age-adjusted total score"
  • Score ≥3: patient nutritionally at risk → initiate nutritional care plan
  • Score <3: weekly rescreening
  • Score <3 but scheduled for major operation: consider preventive nutritional care plan